Advancing Pathology Image Assessment Through AI-Powered Decision Support

sEmpowering pathologists and streamlining clinical workflow processe

Established in 2020, ROSEAId emerged from a significant collaboration with the University of Texas Health. ROSEAId is an AI-powered, cloud-based platform designed to support pathology image assessment, collaborative review, specimen adequacy evaluation workflows, and research initiatives across academic and laboratory environments.

Mission

ROSEAId fulfills the specialized requirements of pathologists through advanced data analytics and streamlined workflow tools, providing real-time image assessment insights and laboratory workflow support.

Vision

To establish a future standard in telepathology focused on pathology image assessment, collaborative review, and workflow efficiency, with future clinical applications subject to applicable regulatory clearances.

Supporting Rapid Onsite Evaluation Workflows in Cytopathology

Broadcast via Advancements with Ted Danson on CNBC, Aired Saturday 01/22/2022.

Support Clinical
Review Workflows

Accelerate Pathology
Workflow Review

Boost Productivity
and Reduce Costs

Extensive Dataset
Support

Integration of
3rd Party Devices

Historical Case Review
and Comparisons

ROSEAId Products

Telepathology Platform

This platform enables pathologists and laboratory teams to securely access pathology images, collaborate remotely, and support specimen review workflows through an integrated telepathology environment.

Research Platform

RoseAId’s research platform, intended for our teaching hospital partners, leads the way for innovative data science use-cases in healthcare. Our Multi-Modal Large Language Foundational Model (MLLFM) for medical research transforms the way data is analyzed, simulated for more profound investigation into the intricacies of biological complexities.

This versatility enables researchers to analyze large-scale pathology image datasets, identify patterns of interest, and support scientific discovery through advanced computational methods.

Insights

Supporting the Future of Telepathology Through AI-Powered Decision Support

Contact us

Regulatory Notice: Certain ROSEAId platform features and AI-enabled technologies are investigational and may be intended for research use only. These features have not been cleared or approved by the U.S. Food and Drug Administration for diagnostic use.

Our Offices

Houston (Representative)

New York (Headquarters)

Abu Dhabi (Representative)